A Phase 2 interventional study of Nicotinamid riboside and Placebo in Multiple Sclerosis and Progressive Multiple Sclerosis, sponsored by Haukeland University Hospital. Recruiting at 1 site in Norway. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-01-11.
Sponsored by Haukeland University Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Multiple Sclerosis with a site in Norway — 2 open to participants now, 9 under way, 3 of them phase 3. Multiple Sclerosis · Norway.
Among the 56 studies in Multiple Sclerosis with a site in Norway, this one is the 22nd largest by planned enrollment of the 43 interventional ones that give a count, is one of 2 that started in 2023, is one of 9 in phase 2, and was the 52nd registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →2 of the 56 studies in Multiple Sclerosis with a site in Norway are open now. Recruiting first, the newest first:
Oslo University Hospital · Sites in Norway
Ages 50–80
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 17 · Phase 4 6
First in 2002; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 300 across the 43 interventional studies, 599 across the 13 observational. Of the 41 that completed or were terminated, 20 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 56 have an industry lead sponsor. The 10 most frequent:
Haukeland University Hospital is the lead sponsor of 284 studies on the registry; 58 are open to participants now.
Haukeland University Hospital has 4 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Multiple Sclerosis with a site in Norway that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05740722Haukeland University HospitalNicotinamide Riboside Supplementation In Progressive Multiple Sclerosis | 2027-08-01 |
Add it to your calendar (.ics) → With an account.
Among the 56 studies in Multiple Sclerosis with a site in Norway, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and efficacy of Nicotinamide riboside (NR) for treatment of patients with progressive multiple sclerosis.
The main question it aims to answer is:
Participants will be treated with NR or placebo for 30 months,
After being informed about the study and risks, all patients giving written informed consent will undergo a screening period to determine eligibility for study entry.
At baseline patients who meet the eligibility requirements will be randomised in a double- blinded manner (patient and investigator) in a 1:1 ratio to nicotinamide riboside (1000 mg daily) or placebo (once a day)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo vs study drug
Dietary Supplement: Placebo
Placebo vs study drug
Dietary Supplement: Nicotinamid riboside
500 mg x 2 po
Placebo tablets
Proportion of patients with sustained disability progression over the treatment period
Defined as an increase in either expanded disability status scale (EDSS), timed 25 foot -walk test (T25W) or 9-hole-peg test. EDSS is measured in scores from 0 - 10. The higher the score the less ambulatory ability. Progression is defined as an increase of \>/=1.0 point if baseline EDSS is \</= 5.5 or an increase of \>/=0.5 point if baseline EDSS is \>/= 5.5. Progression in T25WT and 9HPT is defined as an increase of 20% from baseline measures in minutes/seconds.
Time frame: Baseline to month 30
To determine the efficacy of NR compared with placebo, as reflected by EDSS
Proportion of patients with sustained disability progression over the treatment period
Time frame: Baseline to month 30
To determine the efficacy of NR compared with placebo, as reflected by 25-footwalk
Proportion of patients with sustained disability progression over the treatment period
Time frame: Baseline to month 30
To determine the efficacy of NR compared with placebo, as reflected by 9-Hole Peg test
Proportion of patients with sustained disability progression over the treatment period
Time frame: Baseline to month 30
To determine the efficacy of NR compared with placebo, as reflected by total volume of T2 lesions on MRI scans of the brain
MRI
Time frame: Baseline to month 24
To determine the efficacy of NR compared with placebo, as reflected by formation of lesions
MRI
Time frame: Baseline to month 24
Changes in brain atrophy in NR-treated patients with primary progressive multiple sclerosis as compared with placebo
MRI
Time frame: Baseline to month 24
Time to onset of sustained disability progression over the treatment period
Increase in either EDSS, T25FW or 9HPT that is sustained for at least 6 months
Time frame: Baseline to month 30
Plan to share: No
No publications or documents are linked to this record.
Started May 2023 (actual). Primary completion is estimated for Aug 2027, 50 months after the start.
Of 49 non-industry phase 2 interventional studies under Multiple Sclerosis, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 68. This study's planned 50 months is above that.
Counting every sponsor, half of 92 studies reached it within 36 months; a quarter within 20 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Haukeland University Hospital →